This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

J&J says CareFirst distorts the law in US antitrust case over Stelara

( October 13, 2025, 19:53 GMT | Official Statement) -- MLex Summary: Johnson & Johnson and Janssen Biotech filed a reply in support of judgment against CareFirst’s US antitrust case over Stelara, arguing that the opposition distorts the relevant law and the factual record. It said that CareFirst offers “nothing but speculation and conjecture — not evidence, let alone evidence showing that intent to deceive is the ‘single most reasonable inference’ from the record with respect to any of the alleged omissions or misrepresentations” to the Patent and Trademark Office.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections